Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors

@inproceedings{Vonderheide2013PhaseIS,
  title={Phase I study of the CD40 agonist antibody CP-870,893 combined with carboplatin and paclitaxel in patients with advanced solid tumors},
  author={Robert H. Vonderheide and Jennifer M. Burg and Rosemarie Mick and Jennifer A. Trosko and Dongguang Li and M Naveed Shaik and Anthony William Tolcher and Omid A. Hamid},
  booktitle={Oncoimmunology},
  year={2013}
}
CD40 is a cell-surface molecule that critically regulates immune responses. CP-870,893 is a fully human, CD40-specific agonist monoclonal antibody (mAb) exerting clinical antineoplastic activity. Here, the safety of CP-870,893 combined with carboplatin and paclitaxel was assessed in a Phase I study. Patients with advanced solid tumors received standard doses of paclitaxel and carboplatin on day 1 followed by either 0.1 mg/Kg or 0.2 mg/Kg CP-870,893 on day 3 (Schedule A) or day 8 (Schedule B… CONTINUE READING
37 Citations
13 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 13 references

Similar Papers

Loading similar papers…